A translational approach for novel mechanisms of epigenetic regulation in treatment responses: toward a precision medicine model

NIH RePORTER · NIH · R01 · $692,257 · view on reporter.nih.gov ↗

Abstract

PROJECT SUMMARY/ABSTRACT Treatment resistant depression (TRD) is a leading cause of illness and disability worldwide; there is a dearth of new mechanistic models for the development of better therapeutic strategies. Studies to date showed that administration of LAC, a pivotal mitochondrial metabolite, leads to a rapid and persistent antidepressant-like response by increasing histone acetyltransferases (HATs) activity and the related expression of a key inhibitor of glutamate release mGlu2 receptor in circuits implicated in TRD. Furthermore, LAC levels are decreased in clinical phenotypes of TRD. The objective of this application is to understand the role of central and peripheral LAC-related mitochondrial metabolism in the regulation of TMS responses in phenotypes of TRD. We will also use computational algorithm and statistical clustering to ascertain the role of the novel biomarkers of TMS responses in the trajectories of functional connectivity, and how these pathways are modified by sex. This contribution will advance our understanding of cellular and molecular mechanisms of mitochondrial metabolism for TMS responses in phenotypes of TRD, and identify sex-differences in these mechanisms.

Key facts

NIH application ID
10754575
Project number
5R01MH128311-03
Recipient
NEW YORK UNIVERSITY SCHOOL OF MEDICINE
Principal Investigator
Carla Nasca
Activity code
R01
Funding institute
NIH
Fiscal year
2024
Award amount
$692,257
Award type
5
Project period
2022-02-08 → 2026-12-31